StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$4.96−0.04 (-0.80%)

Close on Nov 17, 2026Market cap $193.13MP/E –Yield –

Entrada Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Entrada Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $4.69M, down 94.1% year over year. For fiscal 2025 it was $25.42M, down 87.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$25.42M-87.9%
FY2024Dec 31, 2024$210.78M+63.4%
FY2023Dec 31, 2023$129.01M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$898.00K-53.9%
Q1 FY2026Mar 31, 2026$875.00K-95.7%
Q4 FY2025Dec 31, 2025$1.30M-96.5%
Q3 FY2025Sep 30, 2025$1.61M-91.8%
Q2 FY2025Jun 30, 2025$1.95M-97.9%
Q1 FY2025Mar 31, 2025$20.56M-65.2%
Q4 FY2024Dec 31, 2024$37.40M-10.6%
Q3 FY2024Sep 30, 2024$19.57M-55.3%
Q2 FY2024Jun 30, 2024$94.69M+421.2%
Q1 FY2024Mar 31, 2024$59.12M+134.0%
Q4 FY2023Dec 31, 2023$41.85M–
Q3 FY2023Sep 30, 2023$43.74M–
Q2 FY2023Jun 30, 2023$18.17M–
Q1 FY2023Mar 31, 2023$25.26M–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–
Q1 FY2022Mar 31, 2022$0–

More Entrada Therapeutics figures

See a number that looks wrong?